mail2

Spectrum Library

Apheresis in treatment of acute inflammatory demyelinating disorders. – PubMed – NCBI

Apheresis in treatment of acute inflammatory demyelinating disorders. – PubMed – NCBI.

Apheresis in treatment of acute inflammatory demyelinating disorders.

Author information

  • 1Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Germany.
  • 2Department of Neurology, Georg-August-University Göttingen, Germany.
  • 3Department of Pediatrics and Pediatric Neurology, Georg-August-University Göttingen, Germany.
  • 4Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Germany. Electronic address: mkoziolek@med.uni-goettingen.de.

Abstract

Therapeutic apheresis has reached an important value in the treatment of neurologic disorders. In the indication of acute relapses of inflammatory demyelinating conditions plasma exchange (PE) is currently mentioned in guidelines in adults and children. Immunoadsorption (IA) is a younger but more selective apheresis method. Compared to PE, data on IA in these indications are less substantiated. Hitherto existing studies indicate IA as effective and safe with similar response rates versus PE. Our own study of 140 adult patients treated with PE or IA in steroid refractory multiple sclerosis or neuromyelitis optica affirm previous findings showing no significant difference in efficacy and treatment safety. Analogue to adult patients, children seem to benefit from apheresis therapy in steroid resistant inflammatory demyelinating conditions but their treatment implies certain challenges concerning physiology, anatomy and psychological aspects necessitating a multidisciplinary therapeutic setting.

Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

KEYWORDS:

Acute disseminated encephalomyelitis; Children; Immunoadsorption; Multiple sclerosis; Neuromyelitis optica; Pediatric; Plasmapheresis

PMID:
25936333
[PubMed – in process]
Launch Dashboard

Dashboard

Fast Facts about NMOSD